AFYA — Afya Limited

AFYA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: BRL 2.784 billion for the nine-month period, a 13% year-over-year increase.
• Adjusted EBITDA: BRL 1.292 billion, up 19% year-over-year, with an adjusted EBITDA margin of 46.4%, a 200 basis point improvement.
• Net Income: BRL 593 million, reflecting a 20% increase year-over-year, with basic EPS of BRL 6.40.
• Cash Flow: Record cash flow from operating activities at BRL 1.292 billion, an 11% increase, with a cash conversion rate of 101.5%.
• Medical Students: Over 25,000 undergraduate medical students, a 6% growth year-over-year.

2. Strategic Updates and Business Highlights

• Occupancy: Maintained 100% occupancy in all medical programs.
• Seat Approvals: Increased approved medical seats to 3,753, with the addition of 100 seats in Afya Bragança.
• Continuing Education: Revenue grew by 11% year-over-year to BRL 208 million, with significant B2B revenue growth of 65%.
• Medical Practice Solutions: Revenue increased by over 9% year-over-year to BRL 128 million.
• ESG Initiatives: Delivered 700,000 free healthcare consultations, exceeding 2025 targets, and recognized for leadership in ESG practices.

3. Forward Guidance and Outlook

• Tax Rate: The effective tax rate increased to 9.7% due to provisions for OECD Pillar Two taxation, expected to converge to 15% from 2026 onwards.
• Capital Allocation: Plans for potential M&A opportunities and shareholder remuneration strategies, including dividends and share buybacks, are under consideration.
• 2026 Tuition Growth: Expected tuition increases of approximately 5% to 5.2% over 2025.

4. Challenges and Points of Concern

• Decline in Residency Students: A 36% decrease in residency students was noted, attributed to a change in how programs are counted rather than a drop in demand.
• Decreased Active Users: A decline in the number of active users in the medical practice solutions segment, with total active payers down 2% year-over-year.
• Clinical Decision Software: Notable loss of subscribers for clinical decision software, prompting a review of pricing and feature offerings to regain market share.

5. Notable Q&A Insights

• Tax Strategy: Management is preparing for a higher effective tax rate due to new regulations and is evaluating strategies to mitigate impacts on foreign investors.
• M&A and Shareholder Returns: The company is exploring M&A opportunities while also considering increasing dividends or share buybacks based on market conditions and cash availability.
• Demand for Medical Careers: Demand remains stable with no significant changes in applicant interest compared to the previous year, despite competitive pressures.
• Continuing Education Adjustments: The drop in residency students is a one-time effect due to program restructuring, expected to stabilize moving forward.

Overall, Afya Limited demonstrated strong financial performance and strategic growth initiatives while acknowledging certain operational challenges and market dynamics.